Skip to main content
Erschienen in: Journal of General Internal Medicine 3/2020

03.11.2020 | Original Research

Association Between Opioid Dose Reduction Against Patients’ Wishes and Change in Pain Severity

verfasst von: Joseph W. Frank, MD, MPH, Evan Carey, PhD, Charlotte Nolan, MPA, Anne Hale, BA, Sean Nugent, BA, Erin E. Krebs, MD, MPH

Erschienen in: Journal of General Internal Medicine | Sonderheft 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

There is inadequate evidence of long-term benefit from opioid medications for chronic pain and substantial evidence of potential harms. For patients, dose reduction may be beneficial when implemented voluntarily and supported by a multidisciplinary team but experts have advised against involuntary opioid reduction.

Objectives

To assess the prevalence of self-reported involuntary opioid reduction and to examine whether involuntary opioid reduction is associated with changes in pain severity.

Design

Prospective observational cohort study.

Participants

Primary care patients treated with long-term opioid therapy in the Veterans Health Administration (N = 290).

Main Measures

The primary exposure was self-reported past year involuntary opioid reduction. The primary outcome was the three-item PEG scale, which measures past-week average pain intensity and interference with enjoyment of life and general activity.

Key Results

Past year opioid reduction or discontinuation was reported by 63% (184/290). Similar numbers reported involuntary (88/290) and voluntary (96/290) opioid reduction. At baseline, there were no significant differences in pain severity between the groups (mean PEG, 7.08 vs. 6.73 vs. 7.07 for past year involuntary opioid reduction, past year voluntary opioid reduction, and no past year opioid reduction, respectively; P = 0.32). For the primary outcome of change in pain severity from baseline to 18 months, there were no significant differences between groups (mean PEG change, − 0.05 vs. − 0.44 vs. − 0.23 for past year involuntary opioid reduction, past year voluntary opioid reduction, and no past year opioid reduction, respectively; P = 0.28).

Conclusions

Self-reported past year involuntary opioid reduction was common among a national sample of veterans treated with long-term opioid therapy. Opioid dose reduction, whether involuntary or voluntary, was not associated with change in pain severity. Future studies should examine involuntary opioid reduction in different populations and trends over time and explore further patient- and provider-level factors that may impact patient experience and outcomes during opioid reduction.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Krebs EE, Gravely A, Nugent S, et al. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. JAMA. 2018;319(9):872-882.CrossRef Krebs EE, Gravely A, Nugent S, et al. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. JAMA. 2018;319(9):872-882.CrossRef
2.
Zurück zum Zitat Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. JAMA. 2016;315(15):1624-1645.CrossRef Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. JAMA. 2016;315(15):1624-1645.CrossRef
3.
Zurück zum Zitat Frank JW, Lovejoy TI, Becker WC, et al. Patient Outcomes in Dose Reduction or Discontinuation of Long-Term Opioid Therapy: A Systematic Review. Ann Intern Med. 2017;167(3):181-191.CrossRef Frank JW, Lovejoy TI, Becker WC, et al. Patient Outcomes in Dose Reduction or Discontinuation of Long-Term Opioid Therapy: A Systematic Review. Ann Intern Med. 2017;167(3):181-191.CrossRef
4.
Zurück zum Zitat Darnall BD, Juurlink D, Kerns RD, et al. International Stakeholder Community of Pain Experts and Leaders Call for an Urgent Action on Forced Opioid Tapering. Pain Med. 2019;20(3):429-433.CrossRef Darnall BD, Juurlink D, Kerns RD, et al. International Stakeholder Community of Pain Experts and Leaders Call for an Urgent Action on Forced Opioid Tapering. Pain Med. 2019;20(3):429-433.CrossRef
5.
Zurück zum Zitat Dowell D, Haegerich T, Chou R. No Shortcuts to Safer Opioid Prescribing. N Engl J Med. 2019;380(24):2285-2287.CrossRef Dowell D, Haegerich T, Chou R. No Shortcuts to Safer Opioid Prescribing. N Engl J Med. 2019;380(24):2285-2287.CrossRef
7.
Zurück zum Zitat Kroenke K, Alford DP, Argoff C, et al. Challenges with Implementing the Centers for Disease Control and Prevention Opioid Guideline: A Consensus Panel Report. Pain Med. 2019;20(4):724-735.CrossRef Kroenke K, Alford DP, Argoff C, et al. Challenges with Implementing the Centers for Disease Control and Prevention Opioid Guideline: A Consensus Panel Report. Pain Med. 2019;20(4):724-735.CrossRef
8.
Zurück zum Zitat Dowell D, Haegerich TM. Changing the Conversation About Opioid Tapering. Ann Intern Med. 2017;167(3):208-209.CrossRef Dowell D, Haegerich TM. Changing the Conversation About Opioid Tapering. Ann Intern Med. 2017;167(3):208-209.CrossRef
9.
Zurück zum Zitat Frank JW, Levy C, Matlock DD, et al. Patients’ Perspectives on Tapering of Chronic Opioid Therapy: A Qualitative Study. Pain Med. 2016;17(10):1838-1847.CrossRef Frank JW, Levy C, Matlock DD, et al. Patients’ Perspectives on Tapering of Chronic Opioid Therapy: A Qualitative Study. Pain Med. 2016;17(10):1838-1847.CrossRef
10.
Zurück zum Zitat Howe CQ, Sullivan MD, Saunders KW, et al. Depression and ambivalence toward chronic opioid therapy for chronic noncancer pain. Clin J Pain. 2012;28(7):561-566.CrossRef Howe CQ, Sullivan MD, Saunders KW, et al. Depression and ambivalence toward chronic opioid therapy for chronic noncancer pain. Clin J Pain. 2012;28(7):561-566.CrossRef
11.
Zurück zum Zitat Kennedy LC, Binswanger IA, Mueller SR, et al. “Those Conversations in My Experience Don’t Go Well”: A Qualitative Study of Primary Care Provider Experiences Tapering Long-term Opioid Medications. Pain Med. 2018;19(11):2201-2211.CrossRef Kennedy LC, Binswanger IA, Mueller SR, et al. “Those Conversations in My Experience Don’t Go Well”: A Qualitative Study of Primary Care Provider Experiences Tapering Long-term Opioid Medications. Pain Med. 2018;19(11):2201-2211.CrossRef
12.
Zurück zum Zitat Krebs EE, Clothier B, Nugent S, et al. The evaluating prescription opioid changes in veterans (EPOCH) study: Design, survey response, and baseline characteristics. PLoS One. 2020;15(4):e0230751.CrossRef Krebs EE, Clothier B, Nugent S, et al. The evaluating prescription opioid changes in veterans (EPOCH) study: Design, survey response, and baseline characteristics. PLoS One. 2020;15(4):e0230751.CrossRef
14.
Zurück zum Zitat Banta-Green CJ, Von Korff M, Sullivan MD, Merrill JO, Doyle SR, Saunders K. The prescribed opioids difficulties scale: a patient-centered assessment of problems and concerns. Clin J Pain. 2010;26(6):489-497.CrossRef Banta-Green CJ, Von Korff M, Sullivan MD, Merrill JO, Doyle SR, Saunders K. The prescribed opioids difficulties scale: a patient-centered assessment of problems and concerns. Clin J Pain. 2010;26(6):489-497.CrossRef
15.
Zurück zum Zitat Krebs EE, Lorenz KA, Bair MJ, et al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. J Gen Intern Med. 2009;24(6):733-738.CrossRef Krebs EE, Lorenz KA, Bair MJ, et al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. J Gen Intern Med. 2009;24(6):733-738.CrossRef
16.
Zurück zum Zitat Kean J, Monahan PO, Kroenke K, et al. Comparative Responsiveness of the PROMIS Pain Interference Short Forms, Brief Pain Inventory, PEG, and SF-36 Bodily Pain Subscale. Med Care. 2016;54(4):414-421.CrossRef Kean J, Monahan PO, Kroenke K, et al. Comparative Responsiveness of the PROMIS Pain Interference Short Forms, Brief Pain Inventory, PEG, and SF-36 Bodily Pain Subscale. Med Care. 2016;54(4):414-421.CrossRef
18.
Zurück zum Zitat DeSalvo KB, Bloser N, Reynolds K, He J, Muntner P. Mortality prediction with a single general self-rated health question. A meta-analysis. J Gen Intern Med. 2006;21(3):267-275.CrossRef DeSalvo KB, Bloser N, Reynolds K, He J, Muntner P. Mortality prediction with a single general self-rated health question. A meta-analysis. J Gen Intern Med. 2006;21(3):267-275.CrossRef
19.
Zurück zum Zitat Levy, P.S. and Lemeshow, S. (1999) Sampling of Population, Methods and Application. 3rd Edition, John Wiley & Sons, New York. Levy, P.S. and Lemeshow, S. (1999) Sampling of Population, Methods and Application. 3rd Edition, John Wiley & Sons, New York.
21.
Zurück zum Zitat Hadlandsmyth K, Mosher H, Vander Weg MW, Lund BC. Decline in Prescription Opioids Attributable to Decreases in Long-Term Use: A Retrospective Study in the Veterans Health Administration 2010-2016. J Gen Intern Med. 2018;33(6):818-824.CrossRef Hadlandsmyth K, Mosher H, Vander Weg MW, Lund BC. Decline in Prescription Opioids Attributable to Decreases in Long-Term Use: A Retrospective Study in the Veterans Health Administration 2010-2016. J Gen Intern Med. 2018;33(6):818-824.CrossRef
22.
Zurück zum Zitat McPherson S, Lederhos Smith C, Dobscha SK, et al. Changes in pain intensity after discontinuation of long-term opioid therapy for chronic noncancer pain. Pain. 2018;159(10):2097-2104.CrossRef McPherson S, Lederhos Smith C, Dobscha SK, et al. Changes in pain intensity after discontinuation of long-term opioid therapy for chronic noncancer pain. Pain. 2018;159(10):2097-2104.CrossRef
23.
Zurück zum Zitat Morasco BJ, Smith N, Dobscha SK, Deyo RA, Hyde S, Yarborough BJH. Outcomes of prescription opioid dose escalation for chronic pain: results from a prospective cohort study. Pain. 2020 Jun;161(6):1332-1340.CrossRef Morasco BJ, Smith N, Dobscha SK, Deyo RA, Hyde S, Yarborough BJH. Outcomes of prescription opioid dose escalation for chronic pain: results from a prospective cohort study. Pain. 2020 Jun;161(6):1332-1340.CrossRef
24.
Zurück zum Zitat Campbell G, Hall WD, Peacock A, et al. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health. 2018;3(7):e341-e350.CrossRef Campbell G, Hall WD, Peacock A, et al. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health. 2018;3(7):e341-e350.CrossRef
25.
Zurück zum Zitat CDC. Prevalence of chronic pain and high-impact chronic pain among adults—United States, 2016. MMWR Morb Mortal Wkly Rep. 2018(67):1001-1006. CDC. Prevalence of chronic pain and high-impact chronic pain among adults—United States, 2016. MMWR Morb Mortal Wkly Rep. 2018(67):1001-1006.
26.
Zurück zum Zitat Gaither JR, Gordon K, Crystal S, et al. Racial disparities in discontinuation of long-term opioid therapy following illicit drug use among black and white patients. Drug Alcohol Depend. 2018;192:371-376.CrossRef Gaither JR, Gordon K, Crystal S, et al. Racial disparities in discontinuation of long-term opioid therapy following illicit drug use among black and white patients. Drug Alcohol Depend. 2018;192:371-376.CrossRef
27.
Zurück zum Zitat Becker WC, Starrels JL, Heo M, Li X, Weiner MG, Turner BJ. Racial differences in primary care opioid risk reduction strategies. Ann Fam Med. 2011;9(3):219-225.CrossRef Becker WC, Starrels JL, Heo M, Li X, Weiner MG, Turner BJ. Racial differences in primary care opioid risk reduction strategies. Ann Fam Med. 2011;9(3):219-225.CrossRef
28.
Zurück zum Zitat Williams DR, Lawrence JA, Davis BA, Vu C. Understanding how discrimination can affect health. Health Serv Res. 2019;54 Suppl 2:1374-1388.CrossRef Williams DR, Lawrence JA, Davis BA, Vu C. Understanding how discrimination can affect health. Health Serv Res. 2019;54 Suppl 2:1374-1388.CrossRef
30.
Zurück zum Zitat Schleiden LJ, Thorpe CT, Cashy JP, et al. Characteristics of dual drug benefit use among veterans with dementia enrolled in the Veterans Health Administration and Medicare Part D. Res Social Adm Pharm. 2019;15(6):701-709.CrossRef Schleiden LJ, Thorpe CT, Cashy JP, et al. Characteristics of dual drug benefit use among veterans with dementia enrolled in the Veterans Health Administration and Medicare Part D. Res Social Adm Pharm. 2019;15(6):701-709.CrossRef
Metadaten
Titel
Association Between Opioid Dose Reduction Against Patients’ Wishes and Change in Pain Severity
verfasst von
Joseph W. Frank, MD, MPH
Evan Carey, PhD
Charlotte Nolan, MPA
Anne Hale, BA
Sean Nugent, BA
Erin E. Krebs, MD, MPH
Publikationsdatum
03.11.2020
Verlag
Springer International Publishing
Erschienen in
Journal of General Internal Medicine / Ausgabe Sonderheft 3/2020
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-020-06294-z

Weitere Artikel der Sonderheft 3/2020

Journal of General Internal Medicine 3/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.